Product Name	Lanreotide
CAS No	108736-35-2
EC-No
Min. Order	1kg
Purity	99%
Supply Ability	g-kg-tons, free sample is available
Release date	2024/03/26

Description	Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome[1][2].
Related Catalog	Research Areas >> Cancer Research Areas >> Endocrinology Signaling Pathways >> Others >> Others
In Vitro	Lanreotide (BIM 23014) (100 nM; 24-48 h) combines with radiation increasing in apoptotic sub-G1 proportion[1]. Lanreotide results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide at concentrations of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC50 is 57 nM[1]. Lanreotide inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro[2].
In Vivo	Lanreotide (2.5-10mg/kg; s.c.; daily for 5 days) results in tumor growth inhibition[1]. Animal Model: Male nude mice, 8 weeks old and 20–25 g in body weight (GH3 tumor-bearing nude mice)[1] Dosage: 2.5, 5, 10 mg/kg Administration: Subcutaneous; daily for 5 days Result: Produced tumor growth inhibition.
References	[1]. Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16(3):1045-55. [2]. Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf). 2003 Jul;59(1):115-28.

Name	Lanreotide
Synonym	More Synonyms

Lanreotide NEW

Names